Peregrine Capital Management LLC Raises Stock Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Peregrine Capital Management LLC boosted its position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 18.2% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 880,517 shares of the biopharmaceutical company’s stock after purchasing an additional 135,716 shares during the quarter. Peregrine Capital Management LLC’s holdings in Amicus Therapeutics were worth $8,294,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Wellington Management Group LLP increased its stake in shares of Amicus Therapeutics by 13.5% in the 3rd quarter. Wellington Management Group LLP now owns 23,964,044 shares of the biopharmaceutical company’s stock worth $255,936,000 after acquiring an additional 2,856,101 shares in the last quarter. Geode Capital Management LLC grew its holdings in Amicus Therapeutics by 1.2% in the third quarter. Geode Capital Management LLC now owns 6,599,871 shares of the biopharmaceutical company’s stock worth $70,499,000 after purchasing an additional 80,926 shares during the period. Massachusetts Financial Services Co. MA increased its stake in shares of Amicus Therapeutics by 4.6% during the third quarter. Massachusetts Financial Services Co. MA now owns 3,160,027 shares of the biopharmaceutical company’s stock valued at $33,749,000 after purchasing an additional 139,491 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in shares of Amicus Therapeutics by 10.0% during the third quarter. Charles Schwab Investment Management Inc. now owns 2,667,271 shares of the biopharmaceutical company’s stock valued at $28,486,000 after purchasing an additional 242,672 shares during the last quarter. Finally, Assenagon Asset Management S.A. boosted its position in shares of Amicus Therapeutics by 141.1% in the 3rd quarter. Assenagon Asset Management S.A. now owns 2,037,896 shares of the biopharmaceutical company’s stock worth $21,765,000 after purchasing an additional 1,192,489 shares in the last quarter.

Analysts Set New Price Targets

A number of research analysts have issued reports on the company. JPMorgan Chase & Co. lifted their price objective on Amicus Therapeutics from $16.00 to $17.00 and gave the company an “overweight” rating in a research note on Tuesday, November 12th. Guggenheim lifted their price target on Amicus Therapeutics from $13.00 to $15.00 and gave the stock a “buy” rating in a research report on Thursday, November 7th. Morgan Stanley reissued an “equal weight” rating and set a $12.00 price objective (down from $17.00) on shares of Amicus Therapeutics in a research report on Friday, December 13th. StockNews.com raised shares of Amicus Therapeutics from a “hold” rating to a “buy” rating in a report on Wednesday, February 12th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Amicus Therapeutics in a report on Monday, January 13th. Two analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $16.88.

Insider Activity at Amicus Therapeutics

In related news, CEO Bradley L. Campbell sold 7,500 shares of the company’s stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $10.02, for a total transaction of $75,150.00. Following the completion of the sale, the chief executive officer now owns 886,654 shares in the company, valued at approximately $8,884,273.08. This represents a 0.84 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 2.20% of the stock is owned by insiders.

Amicus Therapeutics Price Performance

FOLD opened at $9.85 on Wednesday. The company’s 50-day simple moving average is $9.60 and its two-hundred day simple moving average is $10.43. Amicus Therapeutics, Inc. has a 52-week low of $8.78 and a 52-week high of $14.02. The stock has a market capitalization of $2.94 billion, a P/E ratio of -28.97, a P/E/G ratio of 1.69 and a beta of 0.61. The company has a debt-to-equity ratio of 2.18, a quick ratio of 2.42 and a current ratio of 3.15.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.